Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Stony Brook University
With
Brain & Behavior Research Foundation
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age: 18-65
Diagnosis of MDD and currently in a major depressive episode
Capacity to give informed consent
Score of at least 29 on the MADRS
You may not be if
Low affinity binders (LABs) for TSPO Genotype
Hypersensitivity to celecoxib, sulfonamides, aspirin, other NSAIDs, or any component of the formulation; previous asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs
Heptic impairment, heart failure, severe renal impairment, recent GI bleed, history of peptic ulcer disease, anemia or any other contraindication for celecoxib
Poor CYP2C9 metabolizer
Currently taking medications that interact with celecoxib (digoxin, antihypertensives, diuretics, anticoagulant or anti-platelet treatment, including aspirin)
Use of herbs, drugs, or medications with anti-inflammatory or immunomodulatory properties (within 5 half-lives of starting celecoxib treatment)
Unlikely to tolerate medication washout or the medication-free period following washout
Participant considered at significant risk for suicide
ECT within 1 month
High potential for excessive drug/alcohol use during the treatment period (excluding nicotine or cannabis)
Significant active physical illness or neurological deficit that may affect brain functioning or imaging
Any PET contraindications, including if study imaging will result in the participant receiving greater exposure than the research limit, or if participant is currently pregnant, breastfeeding, or planning to conceive during the course of study participation
Clareo Health | The Effect of Celecoxib on Neuroinflammation in MDD
